A phase 2 randomised, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome

Maria Juarez, Nieves Diaz, Geoffrey Johnston, Saba Nayar, Andrew Payne, Eric Helmer, Dionne Cain, Paulette Williams, Valerie Devauchelle-Pensec, Benjamin Fisher, Roberto Giacomelli, Jacques-Eric Gottenberg, Giuliana Guggino, Marika Kvarnstrom, Xavier Mariette, Wan-Fai Ng, Jose Rosas, Juan Burson, Giovanni Triolo, Francesca BaroneSimon Bowman

Research output: Contribution to journalArticlepeer-review

177 Downloads (Pure)


Objectives: This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with moderate-to-severe primary Sjögren’s syndrome (PSS).

Methods: Adults with PSS were randomised 1:1 to seletalisib 45 mg/day or placebo, in addition to current PSS therapy. Primary endpoints were safety and tolerability and change from baseline in ESSDAI score at Week 12. Secondary endpoints included change from baseline at Week 12 in ESSPRI score and histological features in salivary gland biopsies.

Results: Twenty-seven patients were randomised (seletalisib n=13, placebo n=14); 20 completed the study. Enrolment challenges led to early study termination with loss of statistical power (36% vs 80% planned). Nonetheless, a trend for improvement in ESSDAI and ESSPRI (difference vs placebo: –2.59 [95% CI –7.30, 2.11; P=0.266] and –1.55 [95% CI –3.39, 0.28], respectively) was observed at Week 12. No significant changes were seen in saliva and tear flow. Serious adverse events (AEs) were reported in 3/13 of patients receiving seletalisib versus 1/14 for placebo and 5/13 versus 1/14 discontinued due to AEs, respectively. Serum IgM and IgG concentrations decreased in the seletalisib group versus placebo. Seletalisib demonstrated efficacy in reducing size and organisation of salivary gland inflammatory foci and in target engagement, thus reducing PI3K-mTOR signalling compared with placebo.

Conclusion: Despite enrolment challenges, seletalisib demonstrated a trend towards clinical improvement in patients with PSS. Histological analyses demonstrated encouraging effects of seletalisib on salivary gland inflammation and organization.
Original languageEnglish
Early online date19 Sept 2020
Publication statusE-pub ahead of print - 19 Sept 2020


  • phosphatidylinositol 3-kinase delta (PI3Kδ)
  • primary Sjögren’s syndrome
  • seletalisib
  • proof-of-concept
  • histology


Dive into the research topics of 'A phase 2 randomised, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome'. Together they form a unique fingerprint.

Cite this